<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234816</url>
  </required_header>
  <id_info>
    <org_study_id>N_66_2017</org_study_id>
    <nct_id>NCT03234816</nct_id>
  </id_info>
  <brief_title>Norepinephrine in Cesarean Delivery: A Dose Finding Study</brief_title>
  <official_title>Norepinephrine Infusion in Cesarean Delivery: A Randomized Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Norepinephrine has been recently introduced as a prophylactic vasopressor during Cesarean
      delivery with promising results ; However, the optimum dose for efficient prophylaxis with
      the least side effects is not known. In this study, we will compare three doses (0.05, 0.1,
      0.15 mcg/Kg/min) of norepinephrine for prophylaxis against Post-Spinal hypotension during
      cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal hypotension is a common complication after spinal anesthesia for cesarean delivery
      (CD). Using vasopressors have been considered a gold standard for prevention of post-spinal
      hypotension (PSH) during CD.

      Norepinephrine (NE) is a potent vasopressor characterized by both α adrenergic agonistic
      activity in addition to a weak β adrenergic agonistic activity; thus, NE is considered a
      vasopressor with minimal cardiac depressant effect; these pharmacological properties would
      make NE an attractive alternative to phenylephrine and ephedrine (the most commonly used
      vasopressors in obstetric anesthesia).

      Norepinephrine has been recently introduced as a prophylactic vasopressor during CD with
      promising results; However, the optimum dose for efficient prophylaxis with the least side
      effects is not known.

      In this study, we will compare three doses (0.05, 0.1, 0.15 mcg/Kg/min) of norepinephrine for
      prophylaxis against PSH during CD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">March 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postspinal hypotension</measure>
    <time_frame>30 minutes after spinal anesthesia</time_frame>
    <description>The number of patients who develop hypotension (defined as decreased SBP less than 80% of the baseline reading during the period from intrathecal injection till delivery of the fetus) after spinal block divided by the total number in the group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>90 minutes after spinal anesthesia</time_frame>
    <description>heart rate after spinal anesthesia measured in beat per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vomiting</measure>
    <time_frame>120 minutes after spinal anesthesia</time_frame>
    <description>incidence of vomiting after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea</measure>
    <time_frame>120 minutes after spinal anesthesia</time_frame>
    <description>incidence of nausea after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ephedrine consumption</measure>
    <time_frame>60 minutes after spinal anesthesia</time_frame>
    <description>total amount of ephedrine consumed after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atropine consumption</measure>
    <time_frame>60 minutes after spinal anesthesia</time_frame>
    <description>total amount of atropine consumed after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>10 minutes after delivery</time_frame>
    <description>APGAR score of the delivered fetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of severe postspinal hypotension</measure>
    <time_frame>30 minutes after spinal anesthesia</time_frame>
    <description>The number of patients who develop hypotension (defined as decreased SBP less than 60% of the baseline reading during the period from intrathecal injection till delivery of the fetus) after spinal block divided by the total number in the group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood pressure</measure>
    <time_frame>90 minutes after spinal anesthesia</time_frame>
    <description>arterial blood pressure after spinal anesthesia measured in mmHg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>- 0.05 mcg /Kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>- 0.1 mcg /Kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>- 0.15 mcg /Kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine 0.05 mcg /Kg/min</intervention_name>
    <description>Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia</description>
    <arm_group_label>- 0.05 mcg /Kg/min group</arm_group_label>
    <other_name>noradrenaline infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine 0.1 mcg /Kg/min</intervention_name>
    <description>Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia</description>
    <arm_group_label>- 0.1 mcg /Kg/min group</arm_group_label>
    <other_name>noradrenaline infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine 0.15 mcg /Kg/min</intervention_name>
    <description>Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia</description>
    <arm_group_label>- 0.15 mcg /Kg/min group</arm_group_label>
    <other_name>noradrenaline infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>10 mg Bupivacaine intra-thecal for spinal anesthesia</description>
    <arm_group_label>- 0.05 mcg /Kg/min group</arm_group_label>
    <arm_group_label>- 0.1 mcg /Kg/min group</arm_group_label>
    <arm_group_label>- 0.15 mcg /Kg/min group</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  full term singleton pregnant women

          -  Scheduled for elective Cesarean Delivery

          -  Aged between 18 and 40 years

        Exclusion Criteria:

          -  Cardiac morbidities

          -  Hypertensive disorders of pregnancy,

          -  Peripartum bleeding

          -  Baseline systolic blood pressure (SBP) &lt; 100 mmHg

          -  Body mass index &gt; 35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Mukhtar, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Head of research committee section in anesthesia department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Shash, Professor</last_name>
    <phone>+201001033999</phone>
    <email>shashahmed@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed Hasanin, Lecturer</last_name>
      <phone>+201095076954</phone>
      <email>ahmedmohamedhasanin@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Hasanin</investigator_full_name>
    <investigator_title>Principal investigator, Lecturer of anesthesia and critical care medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

